These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12411951)

  • 1. The liver X receptor gene team: potential new players in atherosclerosis.
    Repa JJ; Mangelsdorf DJ
    Nat Med; 2002 Nov; 8(11):1243-8. PubMed ID: 12411951
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver X receptors and atherosclerosis.
    Lala DS
    IDrugs; 2004 Jun; 7(6):563-9. PubMed ID: 15197661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics and molecular biology.
    Garcia-Otin AL; Zakin MM
    Curr Opin Lipidol; 2003 Oct; 14(5):531-5. PubMed ID: 14501592
    [No Abstract]   [Full Text] [Related]  

  • 4. The liver X receptor and atherosclerosis.
    Scott J
    N Engl J Med; 2007 Nov; 357(21):2195-7. PubMed ID: 18032771
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of green tea polyphenols on the genes with atherosclerotic potential.
    Kaul D; Sikand K; Shukla AR
    Phytother Res; 2004 Feb; 18(2):177-9. PubMed ID: 15022174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicine. PPARs as therapeutic targets: reverse cardiology?
    Plutzky J
    Science; 2003 Oct; 302(5644):406-7. PubMed ID: 14563997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Regulation of lipid metabolism by liver X-activated receptors].
    Wu J; Zhang ZW; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):69-72. PubMed ID: 15127605
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver X receptor-alpha gene expression is positively regulated by thyroid hormone.
    Hashimoto K; Matsumoto S; Yamada M; Satoh T; Mori M
    Endocrinology; 2007 Oct; 148(10):4667-75. PubMed ID: 17628006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the liver X receptor alpha and beta in embryonic and adult mice.
    Annicotte JS; Schoonjans K; Auwerx J
    Anat Rec A Discov Mol Cell Evol Biol; 2004 Apr; 277(2):312-6. PubMed ID: 15052659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of macrophage liver X receptors as inhibitors of atherosclerosis.
    Tangirala RK; Bischoff ED; Joseph SB; Wagner BL; Walczak R; Laffitte BA; Daige CL; Thomas D; Heyman RA; Mangelsdorf DJ; Wang X; Lusis AJ; Tontonoz P; Schulman IG
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11896-901. PubMed ID: 12193651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convergence of lipid homeostasis through liver X and thyroid hormone receptors.
    Berkenstam A; Färnegårdh M; Gustafsson JA
    Mech Ageing Dev; 2004; 125(10-11):707-17. PubMed ID: 15541766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons.
    Iwano S; Nukaya M; Saito T; Asanuma F; Kamataki T
    Biochem Biophys Res Commun; 2005 Sep; 335(1):220-6. PubMed ID: 16061200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists.
    Bradley MN; Tontonoz P
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):10-1. PubMed ID: 15626767
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune?
    Lee CH; Plutzky J
    Circulation; 2006 Jan; 113(1):5-8. PubMed ID: 16391165
    [No Abstract]   [Full Text] [Related]  

  • 15. LXR agonists for the treatment of atherosclerosis.
    Jaye M
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor.
    Moore DD; Kato S; Xie W; Mangelsdorf DJ; Schmidt DR; Xiao R; Kliewer SA
    Pharmacol Rev; 2006 Dec; 58(4):742-59. PubMed ID: 17132852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The liver X receptors.
    Lala DS
    Curr Opin Investig Drugs; 2005 Sep; 6(9):934-43. PubMed ID: 16187693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARs and LXRs: atherosclerosis goes nuclear.
    Barish GD; Evans RM
    Trends Endocrinol Metab; 2004; 15(4):158-65. PubMed ID: 15109614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
    Kino T; Chrousos GP
    Mol Interv; 2004 Oct; 4(5):254-7. PubMed ID: 15471908
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphorylation of the liver X receptors.
    Chen M; Bradley MN; Beaven SW; Tontonoz P
    FEBS Lett; 2006 Sep; 580(20):4835-41. PubMed ID: 16904112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.